Specifically, ALKBH5 removes the m6A modification of GLUT4 mRNA in cancer cells, and recruits YTHDF2 to combine with GLUT4 mRNA to enhance its stability, leading to increased glycolysis of breast cancer cells and resistance to HER2 targeted therapy. Here, ALKBH5 is linked to breast carcinoma.